細胞和基因治療臨床試驗市場規模、佔有率和成長分析：按治療方法、階段、適應症、最終用戶和地區分類——2026-2033年產業預測

2024 年全球細胞和基因治療臨床試驗市場價值為 85.2 億美元，預計到 2025 年將成長至 97.6 億美元，到 2033 年將成長至 288.5 億美元，在預測期（2026-2033 年）內複合年成長率為 14.52%。

全球細胞和基因療法臨床試驗市場的發展動力源自於科學的快速進步，這些進步已將理論概念轉化為成熟的治療方法。這些臨床試驗不僅著眼於緩解症狀，更致力於利用活細胞和遺傳物質治癒或預防疾病，從而滿足腫瘤學、罕見遺傳疾病和免疫學領域亟待解決的關鍵需求。該領域的顯著成長主要得益於生產能力的提升，這簡化了供應鏈並提高了生產可靠性。載體產量和處理方法的標準化增加了多中心研究所需的臨床材料，促進了多種治療方法的探索。此外，生物製藥公司、契約製造和醫療機構之間不斷拓展的策略合作夥伴關係，也有助於加快受試者招募，並體現出各方對提升創新治療方法市場潛力的持續投入。

全球細胞和基因治療臨床試驗市場的成長要素

全球細胞和基因治療臨床試驗市場正受到載體開發和遞送技術以及提高細胞標靶化精準度的創新製劑的最新進展的顯著推動。這些改進提高了生產過程的可靠性，同時最大限度地減少了對周圍細胞的不良影響。此外，更有效率的給藥方法也有助於提高治療產品的可靠性，從而實現更有效率的試驗方案和更佳的患者招募。同時，這些藥物生產和穩定性的進步降低了臨床試驗贊助者的營運挑戰，從而促進了涵蓋更廣泛適應症的臨床試驗數量的增加。

全球細胞和基因治療臨床試驗市場的限制因素

自體和異體細胞療法的生產複雜性為全球細胞和基因治療臨床試驗市場帶來了巨大挑戰。維持高標準的品管和確保有效的低溫運輸基礎設施對於保障產品完整性至關重要，但也限制了同時進行的臨床試驗規模。克服這些生產障礙需要專門的設施、檢驗的製程和訓練有素的人員，以確保細胞產品的安全性和一致性。因此，申辦方難以在各試驗中心擴大受試者招募規模，這會帶來營運風險，最終阻礙試驗核准的進程。

全球細胞和基因治療臨床試驗市場趨勢

全球細胞和基因療法臨床試驗市場正呈現出顯著的多元化發展趨勢，旨在拓展治療選擇並減少對單一調查方法的依賴。研發人員正在擴展載體和細胞療法，並積極建立策略夥伴關係關係，以支持模組化流程開發。這種多元化不僅提高了試驗設計的柔軟性，也加速了從研究到臨床應用的轉化。透過高度靈活的平台組合最佳化患者招募並最大限度地降低專案風險，企業能夠更好地滿足監管要求。預計這一持續發展將推動市場成長，吸引新的服務供應商，並增強治療產品組合在動態的科學和商業性環境中的韌性。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球細胞和基因療法臨床試驗市場規模：按療法類型分類

• 細胞療法
  • CAR-T細胞療法
  • NK細胞療法
  • 幹細胞療法
• 基因治療
  • 體內基因治療
  • 體外基因治療

全球細胞和基因治療臨床試驗市場規模：按階段分類

• 第一階段
• 第二階段
• 第三階段

全球細胞和基因治療臨床試驗市場規模：按適應症分類

• 腫瘤學
• 罕見疾病
• 神經系統

全球細胞和基因治療臨床試驗市場規模：按最終用戶分類

• CRO
• 大學醫院
• 製藥和生物技術

全球細胞和基因治療臨床試驗市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novartis AG（Kymriah）
• Gilead Sciences（Yescarta）
• Bristol Myers Squibb（Abecma）
• bluebird bio
• Spark Therapeutics（Roche）
• uniQure NV
• Sarepta Therapeutics
• Fate Therapeutics
• Allogene Therapeutics
• Celgene（BMS）
• Arcus Biosciences
• Marker Therapeutics
• Iovance Biotherapeutics
• Cellular Biomedicine Group
• Lonza Group

結論與建議

Global Cell And Gene Therapy Clinical Trials Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 9.76 Billion in 2025 to USD 28.85 Billion by 2033, growing at a CAGR of 14.52% during the forecast period (2026-2033).

The global market for cell and gene therapy clinical trials is fueled by rapid scientific advancements that have converted theoretical concepts into validated therapies. These trials focus on utilizing living cells and genetic materials to cure or prevent diseases rather than merely alleviating symptoms, addressing critical unmet medical needs in oncology, rare genetic disorders, and immunology. Significant growth in this sector is largely driven by improved manufacturing capabilities, which streamline supply chains and enhance production reliability. Standardization in vector yields and processing methods allows for increased clinical material availability for multicenter studies, fostering various treatment explorations. Additionally, strategic collaborations among biopharmaceutical firms, contract manufacturers, and healthcare institutions are expanding, reflected in rising investments that promote rapid enrollment and enhance the market potential for innovative therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell And Gene Therapy Clinical Trials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell And Gene Therapy Clinical Trials Market Segments Analysis

Global cell and gene therapy clinical trials market is segmented by therapy type, phase, indication, end-user and region. Based on therapy type, the market is segmented into Cell Therapy and Gene Therapy. Based on phase, the market is segmented into Phase I, Phase II and Phase III. Based on indication, the market is segmented into Oncology, Rare Diseases and Neurological. Based on end-user, the market is segmented into CROs, Academic Medical Centers and Pharma & Biotech. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cell And Gene Therapy Clinical Trials Market

The Global Cell And Gene Therapy Clinical Trials market is significantly driven by recent advancements in vector development and delivery techniques, as well as innovative formulations that enhance the precision of cell targeting. These improvements help minimize adverse effects on surrounding cells while bolstering confidence in the manufacturing processes. Moreover, streamlined dosing methods contribute to the reliability of the therapeutic products, enabling more efficient protocols and improving patient recruitment for clinical trials. Additionally, advancements in the manufacturing and stability of these agents reduce operational challenges for sponsors, which in turn facilitates a greater number of clinical trials across diverse applications.

Restraints in the Global Cell And Gene Therapy Clinical Trials Market

The complexities involved in producing both autologous and allogeneic cell therapies pose significant challenges within the Global Cell and Gene Therapy Clinical Trials market. Maintaining high quality control standards and ensuring an effective cold-chain infrastructure are essential to preserving product integrity, yet they also restrict the volume of clinical studies conducted. These production hurdles demand specialized facilities, validated processes, and well-trained personnel to guarantee the safety and consistency of cell products. As a result, sponsors struggle to scale up trial participant enrollment across various sites, introducing operational risks that ultimately hinder the acceleration of trial approvals.

Market Trends of the Global Cell And Gene Therapy Clinical Trials Market

The Global Cell and Gene Therapy Clinical Trials market is witnessing a notable trend towards diversifying development platforms to enhance treatment options and reduce reliance on singular methodologies. Developers are expanding both vector and cellular approaches, facilitating the establishment of strategic partnerships that support modular process development. This diversification not only spurs flexibility in trial designs but accelerates the transition from research to clinical applications. By optimizing patient recruitment and minimizing program-level risks through adaptable platform stacks, firms can better align with regulatory demands. This ongoing evolution is expected to bolster market growth, attract new service providers, and fortify the resilience of therapeutic portfolios in a dynamic scientific and commercial environment.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Cell And Gene Therapy Clinical Trials Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Cell Therapy
  • CAR-T Cell Therapy
  • NK Cell Therapy
  • Stem Cell Therapy
• Gene Therapy
  • In Vivo Gene Therapy
  • Ex Vivo Gene Therapy

Global Cell And Gene Therapy Clinical Trials Market Size by Phase & CAGR (2026-2033)

• Market Overview
• Phase I
• Phase II
• Phase III

Global Cell And Gene Therapy Clinical Trials Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Oncology
• Rare Diseases
• Neurological

Global Cell And Gene Therapy Clinical Trials Market Size by End-User & CAGR (2026-2033)

• Market Overview
• CROs
• Academic Medical Centers
• Pharma & Biotech

Global Cell And Gene Therapy Clinical Trials Market Size & CAGR (2026-2033)

• North America (Therapy Type, Phase, Indication, End-User)
  • US
  • Canada
• Europe (Therapy Type, Phase, Indication, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Phase, Indication, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Phase, Indication, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Phase, Indication, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG (Kymriah)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (Yescarta)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (Abecma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spark Therapeutics (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• uniQure NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (BMS)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcus Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Marker Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellular Biomedicine Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations